Cancer News and Research

Latest Cancer News and Research

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer.

1 Jun 2015

Combination of nivolumab and ipilimumab drugs can improve outcomes in patients with advanced melanoma

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.

1 Jun 2015

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 in patients with intermediate and high risk acute myelogenous leukemia (AML).

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago.

1 Jun 2015

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

Hutchison China MediTech Limited, today announces that AstraZeneca AB, Hutchison MediPharma Limited's collaboration partner, presented preliminary data from the ongoing Phase Ib clinical trial of HMP's c-Met inhibitor savolitinib (AZD6094) combined with AstraZeneca's drug candidate AZD9291 in non-small cell lung cancer.

1 Jun 2015

WBRT associated with worse cognitive function than radiosurgery, shows study

Whole Brain Radiation Therapy (WBRT) is associated with significantly worse cognitive function than radiosurgery, and should no longer be used in the adjuvant setting after radiosurgery to treat cancer patients with brain metastases, according to a large study led by a researcher at The University of Texas MD Anderson Cancer Center.

1 Jun 2015

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

PharmaEngine, Inc. today announced that a New Drug Application (NDA) has been submitted to the Taiwan Food and Drug Administration (TFDA) for MM-398 (irinotecan liposome injection, also known as nal-IRI) in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.

1 Jun 2015

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

1 Jun 2015

Game changing, breakthrough early cancer detection technology presented at ASCO 2015

Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer and Scientist Dr. Chris Yu and the Anpac research team are introducing what the 2015 Nobel Prize Laureate Summit on Biomedical Science (NPLS) organizers published as, "game changing" and "breakthrough" early cancer detection technology research results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 29 – June 2, 2015.

1 Jun 2015

Riverview Medical Center Foundation announces Third Annual Family Fireworks on the Navesink

The Riverview Medical Center Foundation Board of Trustees is pleased to announce the Third Annual Family Fireworks on the Navesink to support Riverview Medical Center Foundation.

1 Jun 2015

People with common form of lung cancer can benefit from nivolumab drug

In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

1 Jun 2015

RI-MUHC researchers receive innovations grants to build technologies to address cancer challenges

"Thanks to the Innovation Fund, our donors to the MGH Foundation and the vision of the Max Pacioretty Foundation, this new specialized MRI will place the Montreal General Hospital as one of the leading level 1 trauma centres in Canada. This valuable piece of healthcare technology will also allow our world-class researchers to better understand brain injuries, which will lead to improved patient diagnosis and treatment," adds Jean-Guy Gourdeau, President and Chief Executive Officer of the Montreal General Hospital Foundation at the MUHC.

1 Jun 2015

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

1 Jun 2015

Premature mortality target highly unethical and explicitly ageist

One of the main health targets proposed by the UN Sustainable Development Goals (SDG) is to reduce by one-third premature mortality from non-communicable diseases such as cancer, stroke and dementia. The goals for 2016-2030 define premature mortality as deaths occurring among people aged 69 years old or younger.

1 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Determining which strains of cancer will eventually become resistant to chemotherapy could be key in figuring out more effective and targeted forms of treatment. Finding the genes responsible for chemo-resistance is what Jeremy Chien, Ph.D., member of the Cancer Biology Program at The University of Kansas Cancer Center, is looking to do with an innovative system that draws inspiration from the early days of cancer gene research.

1 Jun 2015

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.

1 Jun 2015

Adding AKT inhibitors to radiotherapy could be effective for treating many cancers

Cancer Research UK scientists have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation today.

1 Jun 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors.

1 Jun 2015

Cancer News and Research

Latest Cancer News and Research

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Combination of nivolumab and ipilimumab drugs can improve outcomes in patients with advanced melanoma

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

WBRT associated with worse cognitive function than radiosurgery, shows study

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Game changing, breakthrough early cancer detection technology presented at ASCO 2015

Riverview Medical Center Foundation announces Third Annual Family Fireworks on the Navesink

People with common form of lung cancer can benefit from nivolumab drug

RI-MUHC researchers receive innovations grants to build technologies to address cancer challenges

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Premature mortality target highly unethical and explicitly ageist

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Adding AKT inhibitors to radiotherapy could be effective for treating many cancers

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in